Disruptive Pharma

Management Presentation and Investment Case

Inbjudan till teckning av Units
Företrädesemission i Disruptive Pharma Holding AB

June 2025

Peter Åsberg, CEO

Disruptive Pharma

Disruptive Pharma
– Transforming Drug Product Development

Powered by our **patented** and **clinically validated** Mesoporous Magnesium Carbonate (**MMC**) technology



Approved for human use

Strategic Business Areas

Technology Solutions
External partnerships and development agreements

Product Candidates
Differentiated amorphous versions of marketed drugs

Proven platform. Multiple revenue streams.

Disruptive Pharma

The MMC Formulation Technology
Development of Amorphous Drug Formulations

Mesoporous Magnesium Carbonate – **MMC**

Clinically validated platform technology



Crystalline drug (API / NCE)

Amorphous drug into **MMC**

Common forms of magnesium carbonate

Rock

Chalk

MMC closes the gap in OSD *)

Amorphous MMC formulation

- ✓ High Solubility
- ✓ High Bioavailability
- ✓ High stability compared to ASD
- ✓ Less excipients compared to ASD

Amorphous Solid Dispersion (ASD)

- ○ Lower Stability
- ○ High amounts of polymers and excipients

Standard crystalline formulation

- ○ Low Solubility
- ○ Low Bioavailability

*) OSD = Oral solid dosage

Disruptive Pharma

Key Benefits of MMC Technology
– Introducing an innovative green alternative to ASDs

Enhanced Oral Bioavailability: Erivedge vs MMC formulation



Many drugs fail due to poor bioavailability impacting an industry that invest **+200 BUSD annually**

Competitive Feature	Competitive Advantage
High drug loading of final product	✓ Smaller tablet or capsule ✓ High dose product
Enhanced Bioavailability	✓ Higher dissolution rate ✓ Reduced drug amount
Excellent Powder Flowability	✓ Cost-efficient manufacturing ✓ Ideal for tableting
Sustainable and environment friendly	✓ Less solvent use ✓ Reduced toxic waste

1) Flowability and MMC info: https://www.disruptivepharma.com/mmc-technology/
ASD = Amorphous Solid Dispersion

Disruptive Pharma

Dual Strategy to Advance into the Next Phase of Growth and Commercialization

Product Candidates

Disruptive Pharma projects – MMC based drug formulations

- Improving existing drugs
- Differentiated amorphous products

DPH001	DPH008	*DPH00X*
Liver and renal cancer	Prostate cancer	*Oncology TBD*

Technology Solutions

Providing MMC-based solutions for pharma partners and clients

- Enabling novel drugs
- Drug formulation / Drug product

Services	Agreements	Partnering
Feasibility studies	Development Projects	Product Development

Strategic Pivot: From Product Candidates to Revenue-Generating Technology Solutions

Disruptive Pharma

Transaction Structure / Investment Case Summary

Issue Size & Pricing

- Total proceeds up to SEK 11,7m + up to 11,7m (warrants)
- Subscription price of 90 SEK/unit
- Subscription period June 11 – June 26, 2025

Terms Summary

- Unit: 2 shares and 1 warrant
- Pre-money valuation: approx. SEK 35m
- Dilution up to 25%

Advisory Investment Bank: Redeye

REDEYE NORDIC GROWTH

- More information available on our webpage:
- https://www.disruptivepharma.com/investerare/

Key Investment Attractions

Clinical Validation	**Strong Momentum**	**Proven Technology**
MMC Validated in Clinical Study – Strengthens commercial potential	Growing inbound interest in MMC – Market Demand and Positioning	MMC Technology outperforms other amorphization technologies
Business Model	**Diversified Risks**	**Substantial Upside**
Revenue-generating Development Contracts, Agreements and Licensing	Several Product Candidates offering Co-Development and Partnering opportunities	High-growth potential – Opportunity for significant value appreciation

Disruptive Pharma

Clear Partnering Strategy and Product Development Pathway to Enable Commercial Agreements



Use of Proceeds (in 12 months)

- Strengthen Commercial Team to expand business development and marketing capacity
- Advance DPH008 (Prostate Cancer) through preclinical development and clinical trial readiness
- Prepare for Growth via strategic partnerships, expansion and future financing
- Commercialize MMC Technology through development agreements and service contracts

Disruptive Pharma

Disruptive Pharma – Key Milestones Achieved Since 2024 Capital Raise (Past 12 Months)

MMC Technology

- MMC validated in clinical study
- MMC Proof-of-Concept achieved
- CDMO: Potential strategic partners

Pipeline Progress

- DPH001 (Liver Cancer): Advanced into clinical development
- DPH008 (Prostate Cancer): Nominated a second candidate

Business Execution

- Initiated feasibility studies
- Discussing development contracts with industry partners
- Strengthened out-licensing pipeline

Milestones in "Prospekt 2024" have been completed

Strong execution – Positioned for next phase of growth

Disruptive Pharma

Disruptive Pharma

Strategic Business Areas

Technology Solutions

Product Candidates

Technology Solutions: MMC Enables Optimized Drug Formulation and Drug Product Across All Stages

In vitro	In vivo	Toxicology	Clinical	Product
• Dissolution • Loading • Stability	• Rat, rabbit, dog, pig, .. • PK, PD, ..	• GLP Tox • General, genetic, etc.	• BA / BE • Ph I, II, III • Pivotal, …	• Tablets • Capsules • Other, …

An MMC formulation enables poorly soluble drugs to reach their true therapeutic potential

Product Development



Formulation Development

Disruptive Pharma

High level overview of Disruptive Pharma's value chain and business model in Technology Solutions

API / NCE

Pharma Industry

Disruptive Pharma



Opportunities

- Enabling new drugs
- Improving existing drugs
- Lifecycle management
- Reducing clinical attrition

Clients

- Global large pharma
- Mid-sized and specialty pharma
- Biotech companies
- CDMOs

Revenue

- Fixed fee per project
- Milestone based fees
- Royalty as a % based on drug sales



MMC amorphous formulation

API = Active Pharmaceutical Ingredient (an approved drug substance)
NCE = New Chemical Entity (a development drug compound)

Disruptive Pharma

Technology Solutions: Growing Demand for Projects and Development Services After MMC Validation

- **Momentum Building Around MMC**
  - Increasing demand for the Company's offerings, expertise and solutions

- Business Model – Three Strategic Pillars with partners and clients:

Revenues Milestones Royalties

1) **Service Based Model**
Feasibility Services or Projects

2) **Development Agreements**
Project or Product based model

3) **Partnered Product Development**
Milestones, Royalties & Sales



Increased number of incoming requests after clinical validation of the MMC technology

Disruptive Pharma

High-Value Drugs Market: We have the Technology to Enable Novel Drug and Differentiated Products

The Challenge

About 40% of all drugs on the market and a majority new drugs suffer from poor solubility or high dosing requirement [1,2)]

MMC addresses these challenges

BCS class II
On market: 30%
New drugs: 60-70%

BCS class IV
On market: 10%
New drugs: 10-20%

High dose required

MMC Opportunity

Strong strategic fit with oncology compounds

- ✓ Improve bioavailability
- ✓ Improve side-effect profile
- ✓ Reduce tablet size and pill burden

Oncology: An Attractive First Therapeutic Area

The global oncology drugs market is forecasted to reach $347.3 Bn by 2032 [3)]





1) Sun et al., Acta Pharm Sin B. 2022 Jul; 12(7): 3049–3062.
2) Biopharmaceutics Classification System (BCS); AAPS J. 2012 Dec; 14(4): 664–666.
3) Persistence Market Research - Oncology Drugs Market Outlook (2022-2032)

Disruptive Pharma

Product Candidate Portfolio – Improved amorphous versions of marketed products with relevant medical benefits

Candidate (TA)	Pre-clinical	GMP	Pilot Clinical Study	Scale-up	Pivotal clinical study	EMA, FDA submission	Tentative launch
DPH001 (Oncology)	Liver and renal cancer						TBD
DPH008 (Oncology)	Prostate cancer						2028/2029
DPH00X[1)] (Oncology)	TBA						2029/2030

Disruptive Pharma strategy

Advantages with MMC

- ✓ Enabling formulations of novel drug
- ✓ Reformulation / Improvement of existing drug

Benefits / Savings

- ✓ Shorter time to market
- ✓ Reduced development risk

1) Tentative product candidates in Leukemia / Breast Cancer, TBA (to be announced) in the near future

Disruptive Pharma

DPH001 Goals – Address Unmet Needs with Nexavar® Treatment and Validate MMC Technology in Clinical Study

DPH001 for licensing

Pharmacokinetic profile of DPH001 vs NEXAVAR®



DPH001 vs Nexavar	DPH001
Cmax and AUC	96-105%
Improved absorption variability	>5X

DPH001 tentative market

- Selected countries within EU
- MENA region potential exists
- Nexavar is highly efficacious, but patients suffer from frequent GI side effects *)

Summary

- ✓ **MMC Validated in Humans**
- ✓ **MMC: Excellent Safety**
- ➔ Seeking partner to continue commercial development for MENA and EU regions

*) Source - adverse events in patients treated with sorafenib: Therap Adv Gastroenterol. 2016 Mar; 9(2): 240–249.

Disruptive Pharma

Amorphous DPH008: Pre-Clinical Data and Enhanced Drug Loading Enabled by MMC versus XTANDI®

PK study in rat DPH008 vs Xtandi at equal API dose





DPH008 compared to XTANDI®

➔ Bioequivalent to Xtandi (ASD tablet)

✓ Smaller tablets → Improved patient acceptance

✓ Higher drug load → 1 tablet/day instead of 4

✓ Cost-effective manufacturing process

At 40 mg enzalutamide dose, ***DPH008*** offers a substantially smaller tablet compared to XTANDI

ASD = Amorphous Solid Dispersion

Disruptive Pharma

DPH008: An Opportunity in the Enzalutamide Prostate Cancer Market

Disruptive Pharma's next-gen enzalutamide product candidate

Gross Revenue Prior to Profit Sharing and Cost of Goods Sold (COGs)



DPH008: Strategic Opportunity

- ✓ Unique MMC-based amorphous formulation approach – Minimizes patent infringement risk
- ✓ Cost-efficient manufacturing – Gross margin and pricing advantages
- ✓ Differentiation – Small (40 mg) tablet and High-dose (160 mg) tablet

Global Prostate Cancer Market: Projected to grow from $16.7B in 2025 to $29.6B by 2034 [1)]

Note: Low and High Case scenarios use alternative assumptions.

1) Market Research Future: Hormone-Sensitive Prostate Cancer Market Research Report By Treatment Type - Forecast to 2034

Disruptive Pharma

Disruptive Pharma

The Company

Our Commercial Expansion Plan (2025–2026)

SUMMARY – Strategic Positioning and Revenue Drivers

The versatility of MMC: Enabling differentiated business models and diverse revenue streams – Positioning Disruptive Pharma uniquely across the pharma sector

Proven on >100 different APIs

DPH001

- **PoC on MMC**
- **Clinical Validation**
- **Partner to Initiate Pivotal Trial**

DPH008

- **Large market potential**
- **Several potential partners**

External Projects

- **Significant increase in external inquiries**
- **Generating revenue through Development Projects and Strategic Partnering**

Active discussions with:
– Big Pharma
– Specialty Pharma
– Biotech companies
– Global CDMOs

Strategic Pivot: Redirecting Resources to Revenue-Generating Technology Solutions

Disruptive Pharma

Revenue Projections (non-risk adjusted)



Note: Non-binding Base Case projection based on the assumption of successful business development after financing in 2025 and a larger financing round at later stage (for example an IPO)

Disruptive Pharma

Disruptive Pharma

Experienced Management Team

Peter Åsberg
CEO
>20 years in executive positions

Sven Undeland
Commercial Director
>25 years in BD positions

Malin Vågerö
Director of R&D
>25 years in drug development

Sofia Mogensen
Director Project Management
>20 years in project management

Ann-Sofie Sternås
Head of IP
>30 years in IP positions at Big Pharma & Small biotech

Marc Willuhn
Director Process Development
>20 years in CMC and executive positions

Stefan Ström
CFO
>25 years in public listed companies

Cap table

Största ägare (grupperat)	%	*Ägare*
Strand Fonder inkl diskretionära	21,6%	*65*
Novax (D-AX Sweden AB)	16,8%	*1*
Måttex Förvaltning AB	10,7%	*1*
Beijer	6,0%	*6*
Tiliaflore Holding AB	5,8%	*1*
AOB Förvaltning AB	4,5%	*1*
Tamt AB	4,0%	*1*
Tedde Jeansson	4,0%	*1*
Montrachet Investment AB	2,0%	*1*
Perendinus Technologies AB	2,0%	*1*
Holmsvanen AB	1,8%	*1*
Färjegården Holding AB	1,7%	*1*
Procontra AB	1,6%	*1*
AB Giraffen	1,5%	*1*
Styvikens Invest AS	1,4%	*1*
	85,5%	*84*
ÖVRIGA	14,5%	*86*
Totalt	**100,0%**	*188*

For additional info: www.disruptivepharma.com

Current: May 2025

Disruptive Pharma

Disruptive Pharma

Disruptive Pharma is well positioned to develop improved drug products and enable novel therapies for the benefit of patients based on our unique MMC drug delivery technology

Peter Åsberg, CEO
peter.asberg@disruptivepharma.com